| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18833044 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 101 journal articles in the PubMed database | Email to a friend | | |
| Cassano N, Miracapillo A, Buquicchio R, et al.
Safe use of efalizumab in a psoriasis patient with chronic heart failure due to hypertrophic cardiomyopathy. [Journal Article]
G Ital Dermatol Venereol 2008 Apr; 143(2):167.
Full Citation | Find Related Articles | | Papp KA, Bressinck R, Fretzin S, et al.
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. [Journal Article]
Int J Dermatol 2006 May; 45(5):605-14.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Costanzo A, Peris K, Talamonti M, et al.
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. [JOURNAL ARTICLE]
Br J Dermatol 2007 Apr; 156(s2):17-23.
Abstract | Full Citation | Find Related Articles | | Cather JC, Menter A
Efalizumab: continuous therapy for chronic psoriasis. [Journal Article, Review]
Expert Opin Biol Ther 2005 Mar; 5(3):393-403.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ortonne JP, Shear N, Shumack S, et al.
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. [Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
BMC Dermatol 2005.:13.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kragballe K
Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. [Journal Article]
Br J Dermatol 2007 Apr.:7-11.
Abstract | Full Citation | Find Related Articles | | Gottlieb AB, Miller B, Lowe N, et al.
Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. [Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study]
J Cutan Med Surg 2003 May-Jun; 7(3):198-207.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Menter A, Gordon K, Carey W, et al.
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Arch Dermatol 2005 Jan; 141(1):31-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fernandez-Obregon AC
Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo. [Journal Article]
J Drugs Dermatol 2008 Jul; 7(7):679-81.
Abstract | Full Citation |   |
|
| |
Advertise on this site.
|
